Collagen proline hydroxylase inhibitor
(Synonyms: 胶原蛋白脯氨酸羟化酶抑制剂) 目录号 : GC11075
胶原脯氨酸羟化酶抑制剂是胶原脯氨酸羟化酶抑制剂；可用于抗纤维增殖剂。
Cas No.:223666-07-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: N/A
Collagen proline hydroxylase inhibitor is one member of the collagen proline hydroxylase inhibitor family, which are used as antifibroproliferative agents. Proline hydroxylase is a multiple function oxygenase catalyzing specific prolyl residues in the collagen peptide precursor. Proline hydroxylase has been known as one of the critical enzymes in the biosynthesis of collagen and its activity is enhanced in tissues of various pathological fibrosis. Thus, the specific inhibitor of proline hydroxylase could have clinical application in fibrotic diseases treatment.
In vitro: One of collagen proline hydroxylase inhibitors, P-1894B, was found to in vitro inhibit proline hydroxylase and had been proposed as a topical treatment for dermal fibrosis. P-1894B was observed to be with similar activities on one fibroblast line from a patient with infection and two fibroblast lines from normal human skin. 72-hour drug exposure on growing cells showed both time- and dose-dependent inhibition of proliferation. A similar result was also observed in the epithelial cell line NCTC 2544 [1].
In vivo: So far, collagen proline hydroxylase inhibitor has not been applied to animal in vivo study.
Clinical trial: Currently, no clinical study is available.
Reference:
[1] Priestley GC. Toxicity of the anthraquinone glycoside P-1894B for human skin fibroblasts. Br J Dermatol.1987 Jul;117(1):67-72.
| Cas No. | 223666-07-7 | SDF | |
| 别名 | 胶原蛋白脯氨酸羟化酶抑制剂 | ||
| 化学名 | N-ethyl-8-nitro-7-oxo-N-propyl-7,10-dihydro-1,10-phenanthroline-3-carboxamide | ||
| Canonical SMILES | CCCN(C(C1=CN=C2C(C=CC3=C2NC=C([N+]([O-])=O)C3=O)=C1)=O)CC | ||
| 分子式 | C18H18N4O4 | 分子量 | 354.36 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.822 mL | 14.1099 mL | 28.2199 mL |
| 5 mM | 0.5644 mL | 2.822 mL | 5.644 mL |
| 10 mM | 0.2822 mL | 1.411 mL | 2.822 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。